The combination of maveropepimut-S and cyclophosphamide has shown activity in patients with recurrent ovarian cancer, according to study results published in Clinical Cancer Research.
Maveropepimut-S is an immunotherapy that targets survivin-expressing tumor cells to be eliminated by cytotoxic T cells. In this phase 2 trial, maveropepimut-S and cyclophosphamide produced responses in both platinum-sensitive and platinum-resistant ovarian cancer.
The trial (ClinicalTrials.gov Identifier: NCT02785250) included 22 patients with recurrent ovarian cancer. Their median age was 58 (range, 38-78) years, and 63.6% were White. All but 1 patient had stage III-IV disease. Patients had received a median of 3 prior lines of therapy (range, 1-6), and 59.1% of patients had disease that was resistant or refractory to their most recent platinum-based therapy.
The patients received 2 injections of maveropepimut-S, given at 0.25 mL 3 weeks apart, followed by a single dose of 0.1 mL every 8 weeks until disease progression. Patients also took cyclophosphamide at 50 mg twice daily in repeating cycles of 7 days on, 7 days off.
In the 19 evaluable patients, the objective response rate was 21.1%. All 4 responses were partial responses. Two of the partial responses occurred in patients with platinum-sensitive disease (25.0%) and 2 occurred in patients with platinum-resistant disease (18.2%).
Eight patients had stable disease. The disease control rate was 63.2% overall, 50.0% for patients with platinum-sensitive disease, and 72.7% for patients with platinum-resistant disease.
All 22 patients were evaluable for safety, and 21 of them received at least 1 dose of maveropepimut-S. Nineteen patients (86.4%) reported at least 1 treatment-related adverse event (TRAE).
There were no grade 4 or 5 TRAEs, but 36.4% of patients reported grade 3 TRAEs. The most common grade 3 TRAEs were injection site ulcer (n=5), fatigue (n=2), and anemia (n=2).
The researchers concluded that these results support further investigation of maveropepimut-S and cyclophosphamide in patients with platinum-resistant ovarian cancer.
Disclosures: This research was supported by IMV Inc. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.
Dorigo O, Oza AM, Pejovic T, et al. Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial. Clin Cancer Res. Published online May 1, 2023. doi:10.1158/1078-0432.CCR-22-2595